Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis.

BACKGROUND There is an increasing body of evidence that magnetic resonance imaging-occult tissue damage is an important component of primary progressive multiple sclerosis (PPMS) pathology. Proton magnetic resonance spectroscopy (1H-MRS) can be used to measure in vivo whole-brain N-acetylaspartate (WBNAA) concentrations, the decrease of whose levels is considered a marker of neuronal-axonal injury. OBJECTIVES To study WBNAA 1H-MRS as a tool to provide information about irreversible brain damage in PPMS and to investigate the relationship between WBNAA and other magnetic resonance imaging measures of MS disease burden, including brain atrophy. METHODS The following magnetic resonance pulse sequences of the brain were obtained from 32 patients with PPMS and 16 age-matched healthy subjects: (1) dual-echo turbo spin-echo; (2) T1-weighted spin-echo; and (3) 1H-MRS to measure WBNAA concentration. Brain total lesion volumes were measured. Normalized brain volumes were calculated using a fully automated technique. Absolute WBNAA amounts were calculated using a phantom replacement method and were then corrected for individual subjects' brain size. RESULTS Levels of WBNAA concentrations and normalized brain volumes were significantly lower in patients with PPMS (mean values, 10.2 mm and 1500.0 mL, respectively) than in healthy controls (mean values, 12.9 mm and 1585.2 mL). Both WBNAA concentrations and normalized brain volumes were included as independent factors in the final model of a multivariable analysis predicting the subjects' condition. No significant correlations were found between WBNAA values and normalized brain volumes, WBNAA and T2-weighted or T1-weighted lesion volumes. CONCLUSIONS Axonal-neuronal damage in the brain of patients with PPMS seems to occur, at least partially, independently of the burden of magnetic resonance imaging-visible lesions. Whole-brain N-acetylaspartate values and normalized brain volumes were unrelated in this cohort, thereby suggesting that 1H-MRS and atrophy assessment may provide in vivo complementary information about the actual extent of brain damage in PPMS.

[1]  David H. Miller,et al.  Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.

[2]  J. Kamholz,et al.  Neuronal cell injury precedes brain atrophy in multiple sclerosis , 2005, Neurology.

[3]  Alan J. Thompson,et al.  Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis , 2004, NeuroImage.

[4]  M. Esiri,et al.  Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. , 2004, Brain : a journal of neurology.

[5]  Massimo Filippi,et al.  Indirect evidence for early widespread gray matter involvement in relapsing–remitting multiple sclerosis , 2004, NeuroImage.

[6]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[7]  P Kapeller,et al.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[8]  J. Babb,et al.  Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. , 2002, Radiology.

[9]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[10]  Marco Rovaris,et al.  Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. , 2002, Archives of neurology.

[11]  M. Filippi,et al.  Correlations between Structural CNS Damage and Functional MRI Changes in Primary Progressive MS , 2002, NeuroImage.

[12]  Oded Gonen,et al.  Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. , 2002, AJNR. American journal of neuroradiology.

[13]  G. Comi,et al.  In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. , 2001, Brain : a journal of neurology.

[14]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[15]  Marco Rovaris,et al.  Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis , 2000, Journal of Neurology.

[16]  A J Thompson,et al.  Diagnostic criteria for primary progressive multiple sclerosis: A position paper , 2000, Annals of neurology.

[17]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[18]  A. Thompson,et al.  One year follow up study of primary and transitional progressive multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[19]  À. Rovira,et al.  Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis , 2000, NMR in biomedicine.

[20]  R I Grossman,et al.  Total brain N-acetylaspartate , 2000, Neurology.

[21]  Geoff J. M. Parker,et al.  1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis , 1999, Journal of Neurology.

[22]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[23]  R I Grossman,et al.  Total brain N‐acetylaspartate concentration in normal, age‐grouped females: Quantitation with non‐echo proton NMR spectroscopy , 1998, Magnetic resonance in medicine.

[24]  D. MacManus,et al.  H-1 magnetic resonance spectroscopy of normal-appearing white matter in primary progressive multiple sclerosis , 1998 .

[25]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[26]  P M Matthews,et al.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.

[27]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[28]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[29]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[30]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[31]  J. Dehmeshki,et al.  The normal appearing grey matter in primary progressive multiple sclerosis , 2003, Journal of Neurology.

[32]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.